Biotechnology Stocks on our Scanner -- Agenus, RXi Pharma, Nektar Therapeutics, Genetic Technologies, and Agios Pharma

Jul 31, 2015, 09:30 ET from

NEW YORK, July 31, 2015 /PRNewswire/ --

Equity Research Institute has initiated coverage on the following equities: Agenus Inc. (NASDAQ: AGEN), RXi Pharmaceuticals Corporation (NASDAQ: RXII), Nektar Therapeutics (NASDAQ: NKTR), Genetic Technologies Ltd (NASDAQ: GENE) and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Free research report on Agenus can be accessed at On Thursday, July 30, 2015, the NASDAQ Composite ended at 5,128.79, up 0.33%, the Dow Jones Industrial Average edged 0.03% lower, to finish the day at 17,745.98, and the S&P 500 closed flat at 2,108.63. During the session four out of nine sectors ended in positive. Register for your complimentary reports at the links given below.  

On Thursday, shares in Agenus Inc. ended the session 1.82% higher at $8.39. The stock reported a trading volume of 1.03 million shares, below its three months average volume of 1.72 million shares. Although, Agenus Inc.'s shares have declined 2.78% in the last one month, it has surged 26.93% in the previous three months and 111.34% on YTD basis. The stock is trading 49.39% above its 200-day moving average. Moreover, shares of Agenus Inc. have a Relative Strength Index (RSI) of 44.32. Sign up and read the free notes on AGEN at:

RXi Pharmaceuticals Corp.'s stock lost 5.30%, to close the day at $0.41. The stock recorded a trading volume of 0.86 million shares, much below its three months average volume of 1.83 million shares. Over the last one month and over the past three months, RXi Pharmaceuticals Corp.'s shares have declined 16.12% and 36.87%, respectively. Furthermore, the stock has lost 74.31% since the start of this year. The company's shares are trading 13.12% below their 50-day moving average. Additionally, RXi Pharmaceuticals Corp. has an RSI of 36.75. The complimentary notes on RXII can be downloaded in PDF format at:

On Thursday, shares in Nektar Therapeutics recorded a trading volume of 1.10 million shares, lower than their three months average volume of 1.83 million shares. The stock ended the day 1.31% higher at $12.33. Shares of the company traded at a PE ratio of 72.53. Although, Nektar Therapeutics' stock has surged 29.52% in the previous three months, it has lost 1.44% in the last one month and 20.45% on YTD basis. The company is trading above its 50-day moving average by 2.78%. Furthermore, shares of Nektar Therapeutics have an RSI of 50.46. Register for free on Equity Research Institute and access the latest research on NKTR at:

Genetic Technologies Ltd's stock lost 2.15%, to close Thursday's session at $3.19. The stock recorded a trading volume of 0.14 million shares, below its three months average volume of 0.63 million shares. Over the last one month and since the beginning of 2015, Genetic Technologies Ltd.'s shares have surged 4.93% and 63.59%, respectively. However, the stock has declined 27.83% in the previous three months. The company is trading 11.01% and 6.79% below its 50-day and 200-day moving averages, respectively. Furthermore, Genetic Technologies Ltd's stock has an RSI of 45.44. The complete research on GENE is available for free at:

Agios Pharmaceuticals Inc.'s stock finished Thursday's session 1.26% lower at $108.91. A total of 0.33 million shares were traded, which was below its three months average volume of 0.62 million shares. Over the last one month and since the start of this year, Agios Pharmaceuticals Inc.'s shares have fallen by 2.01% and 2.79%, respectively. However, the stock has gained 17.94% in the previous three months. The company's shares are trading above their 200-day moving average by 3.34%. Agios Pharmaceuticals Inc.'s stock has an RSI of 42.88. Free in-depth research on AGIO is available at:


About Equity Research Institute: 

Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ERI has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.


ERI, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at)

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.